Abstracts tagged "outcomes"

Abstract Number: 763 • 2018 ACR/ARHP Annual Meeting
Comparison of Clinical Characteristics and Outcome between Isolated and Classic Lupus Nephritis
Kubra Bugdayli¹, Cynthia S. Crowson², Ladan Zand³, Mariam P. Alexander⁴, Lynn D. Cornell⁴ and Vaidehi R. Chowdhary⁵, ¹Department of Internal Medicine, Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Nephrology and Hypertension, Mayo Clinic, Rochester, MN, ⁴Anatomic Pathology, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁵Internal Medicine, Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN
Comparison of clinical characteristics and outcome between isolated and classic lupus nephritisBackground/Purpose: Lupus nephritis (LN) is a serious manifestation of systemic lupus erythematosus (SLE). Rarely,…
Abstract Number: 2438 • 2018 ACR/ARHP Annual Meeting
Risk and Severity of Adverse Pregnancy Outcomes in Women with Systemic Sclerosis in Taiwan
Chen I Hsieh¹, Shue Fen Luo² and Chang-Fu Kuo³, ¹Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ²Chang Gung University, Taoyuan County, Taiwan, ³Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan
Background/Purpose: Patients with different autoimmune rheumatic diseases are subject to different pregnancy outcomes because of deviant immunity. Systemic sclerosis is known to be associated with…
Abstract Number: 834 • 2018 ACR/ARHP Annual Meeting
Clinical Characteristics of IgA Vasculitis in Children and Adults: A Retrospective Cohort Study
Michel Villatoro-Villar¹, Cynthia S. Crowson^1,2, Kenneth J. Warrington³, Ashima Makol¹, Steven R. Ytterberg³ and Matthew J. Koster¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN, ³Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: Differences in both presentation and outcome based on age of diagnosis have been described in patients with IgA vasculitis (IgAV) but data are limited…
Abstract Number: 2512 • 2018 ACR/ARHP Annual Meeting
Treatment Continuation on the Etanercept Original in Comparison with a Biosimilar
Lisa Baganz¹, Yvette Meißner¹, Perter Herzer², Jürgen Braun³, Anett Gräßler⁴, Anja Strangfeld⁵ and Angela Zink⁶, ¹Programme Area Epidemiology, German Rheumatism Research Center, Berlin, Germany, ²Scientific Advisory Board, Munich, Germany, ³Ruhr-University Bochum, Bochum, Germany, ⁴Rheumatologist, Pirna, Germany, ⁵Epidemiology, German Rheumatism Research Center, Berlin, Germany, ⁶Epidemiology Unit / Rheumatology and Clinical Immunology, German Rheumatism Research Centre (DRFZ) / Charité University Hospital, Berlin, Germany
Background/Purpose: The number of biosimilars approved for the treatment of rheumatoid arthritis (RA) is constantly increasing. Until now, there are just a few analyses investigating…
Abstract Number: 941 • 2018 ACR/ARHP Annual Meeting
Causal Inference Methods for the Effect of Rheumatoid Arthritis on Mortality Independent of Lifestyle and Clinical Factors before and after RA Diagnosis
Jeffrey A. Sparks¹, Kazuki Yoshida^1,2, Tzu-Chieh Lin³, Carlos Camargo⁴, Benjamin Raby⁵, Hyon K. Choi⁶, Medha Barbhaiya⁷, Sara K. Tedeschi¹, Bing Lu⁸, Karen Costenbader¹ and Elizabeth Karlson¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Harvard T.H. Chan School of Public Health, Boston, MA, ³Amgen, Thousand Oaks, CA, ⁴Emergency Medicine, Massachusetts General Hospital, Boston, MA, ⁵Pulmonary, Brigham and Women's Hospital, Boston, MA, ⁶Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, ⁷Rheumatology, Hospital for Special Surgery, New York, NY, ⁸Division of Rheumatology, Immunology and Allergy, Brigham & Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: RA is associated with increased total, cardiovascular, and respiratory mortality compared to the general population. This excess RA mortality may be mediated through lifestyle,…
Abstract Number: 2594 • 2018 ACR/ARHP Annual Meeting
Median Time to Pain Improvement in Patients with Psoriatic Arthritis Treated with Tofacitinib
Kurt de Vlam¹, Alexis Ogdie², Andrew G Bushmakin³, Joseph C Cappelleri³, Roy Fleischmann⁴, Peter C. Taylor⁵, Valderilio F Azevedo⁶, Lara Fallon⁷, Anna Maniccia⁸, John Woolcott⁹ and Philip J. Mease¹⁰, ¹UZ Leuven, Leuven, Belgium, ²University of Pennsylvania, Philadelphia, PA, ³Pfizer Inc, Groton, CT, ⁴University of Texas Southwestern Medical Center, Dallas, TX, ⁵University of Oxford, Oxford, United Kingdom, ⁶Universidade Federal do Paraná, Curitiba, Brazil, ⁷Pfizer Canada, Montreal, QC, Canada, ⁸Pfizer Inc, New York, NY, ⁹Pfizer Inc, Collegeville, PA, ¹⁰Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: Pain is a core domain of psoriatic arthritis (PsA).1 Rapid, sustained pain reduction is a priority for patients (pts) and physicians when choosing treatment.…
Abstract Number: 1191 • 2018 ACR/ARHP Annual Meeting
The Importance of Quantitative Assessment of Joint/Organ Damage and Patient Distress in Addition to Inflammatory Activity in Routine Clinical Care
Theodore Pincus, Isabel Castrejón and Joel A. Block, Division of Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Quantitative measures such as laboratory tests and pooled indices have advanced clinical rheumatology care far beyond narrative decisions. These measures generally are directed to…
Abstract Number: 2605 • 2018 ACR/ARHP Annual Meeting
Drug Retention and Response Rates of TNFi Treatment in 13,170 Patients with Psoriatic Arthritis Treated in Routine Care – Pooled Data from the Eurospa Research Network Collaboration
Cecilie Heegaard Brahe¹, Lykke Midtbøll Ørnbjerg¹, Lennart Jacobsson², Michael J. Nissen³, Eirik K Kristianslund⁴, Maria José Santos⁵, Kari Eklund⁶, Ziga Rotar⁷, Björn Gudbjornsson⁸, Fatos Onen⁹, Catalin Codreanu¹⁰, Ulf Lindström¹¹, Cem Gabay³, Tore Kvien⁴, Anabela Barcelos⁵, Kalle Aaltonen⁶, Matija Tomšič⁷, Thorvardur Love⁸, Gerçek Can⁹, Ruxandra Ionescu¹⁰, Anne Gitte Loft¹, Herman F Mann¹², Karel Pavelka¹², Marleen van de Sande¹³, Irene van der Horst-Bruinsma¹⁴, Juan J. Gomez-Reino¹⁵, Carlos Sánchez-Piedra¹⁶, Gary J Macfarlane¹⁷, Florenzo Iannone¹⁸, Lise Hyldstrup¹, Niels Steen Krogh¹⁹, Mikkel Østergaard¹ and Merete Lund Hetland¹, ¹DANBIO, EuroSpA Research Collaboration Network, Coordinating Centre, Copenhagen, Denmark, ²ARTIS, EuroSpA Research Collaboration Network, Gothenburg, Sweden, ³SCQM, EuroSpA Research Collaboration Network, Geneva, Switzerland, ⁴NOR-DMARD, EuroSpA Research Collaboration Network, Oslo, Norway, ⁵Reuma.pt, EuroSpA Research Collaboration Network, Lisbon, Portugal, ⁶ROB-FIN, EuroSpA Research Collaboration Network, Helsinki, Finland, ⁷biorx.si, EuroSpA Research Collaboration Network, Ljubljana, Slovenia, ⁸ICEBIO, EuroSpA Research Collaboration Network, Reykjavik, Iceland, ⁹TURKBIO, EuroSpA Research Collaboration Network, Izmir, Turkey, ¹⁰RRBR, EuroSpA Research Collaboration Network, Bucharest, Romania, ¹¹ARTIS, EuroSpA Research Collaboration Network, Stockholm, Sweden, ¹²ATTRA, EuroSpA Research Collaboration Network, Prague, Czech Republic, ¹³ARC, EuroSpA Research Collaboration Network, Amsterdam, Netherlands, ¹⁴ARC, EuroSpA Research Collaboration Network, Harleem, Netherlands, ¹⁵BIOBADASER, EuroSpA Research Collaboration Network, Santiago, Spain, ¹⁶BIOBASADER, EuroSpA Research Collaboration Network, Santiago, Spain, ¹⁷BSRBR-AS, EuroSpA Research Collaboration Network, Aberdeen, United Kingdom, ¹⁸GISEA, EuroSpA Research Collaboration Network, Bari, Italy, ¹⁹ZiteLab ApS, Copenhagen, Denmark
Drug retention and response rates of TNFi treatment in 13,170 patients with psoriatic arthritis treated in routine care – pooled data from the EuroSpA Research…
Abstract Number: 1259 • 2018 ACR/ARHP Annual Meeting
Driving Performance and Safety in Rheumatoid Arthritis: A Systematic Review
Daniel Zhou¹, Ted R. Mikuls², Cynthia Schmidt³, Bryant R. England⁴, Debra A Bergman⁵, Matthew Rizzo⁶, Jennifer Merickel⁶ and Kaleb Michaud^7,8, ¹Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²Internal Medicine, Division of Rheumatology, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ³McGoogan Library of Medicine, University of Nebraska Medical Center, Omaha, NE, ⁴Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁵Division of Rheumatology, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ⁶Neurological Sciences, University of Nebraska Medical Center, Omaha, NE, ⁷Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁸FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS
Background/Purpose: Automobile driving represents an instrumental activity of daily living (IADL). Symptoms accompanying RA, including fatigue, joint pain and stiffness, decreased strength, reduced mobility, and…
Abstract Number: 2627 • 2018 ACR/ARHP Annual Meeting
Not All Clinical Responders in SLE Are Equal: Comparison of Subcutaneous Belimumab + Standard of Care Responders to Placebo + Standard of Care Responders
William Stohl¹, Milena Kurtinecz², Joe Eastman³, Vanessa Castellano⁴, Chrysa Mahoney⁴, Tania Gonzalez-Rivera² and Bonnie Pobiner⁴, ¹Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ²GlaxoSmithKline, Philadelphia, PA, ³GlaxoSmithKline (at the time of the study), Research Triangle Park, NC, ⁴GlaxoSmithKline, Research Triangle Park, NC
Background/Purpose: To determine whether degree of response among responders to subcutaneous (SC) belimumab (BEL) + standard of care (SoC) is greater than that for responders…
Abstract Number: 1327 • 2018 ACR/ARHP Annual Meeting
The Effect of Etoposide on Inducing Remission in Refractory Adult-Onset Still’s Disease: A Retrospective, Single-Center Study
Haiting Wang¹, Xiaodong Wang¹, Ting Li¹ and Shuang Ye², ¹Department of Rheumatology, Renji Hospital South Campus, Shanghai Jiao Tong University School of Medicine, Shanghai, China, ²Rheumatology, Ren Ji Hospital, South Campus, School of Medicine, Shanghai Jiaotong University, Shanghai, China
Background/Purpose: Adult onset Still¡¯s disease (AOSD) is a rare inflammatory disorder of unknown etiology. Macrophage activation syndrome (MAS) is a life-threatening complication and has been…
Abstract Number: 2663 • 2018 ACR/ARHP Annual Meeting
Comparison of Clinical and Laboratory Profiles in 3575 Systemic Lupus Erythematosus Patients with and without Sjögren’s Syndrome: Data from the Spanish Society for Rheumatology Lupus Registry
Juan Gabriel Ovalles-Bonilla^1,2, Francisco Javier López Longo³, Iñigo Rúa-Figueroa⁴, María Galindo⁵, Jaime Calvo-Alén⁶, Juan Carlos Nieto², Julia Martínez-Barrio³, Roberto González⁷, Belen Serrano⁸, Iustina Janta², Carlos M Gonzalez⁹, Indalecio Monteagudo² and JM Pego-Reigosa¹⁰, ¹Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain, ²Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁴Rheumatology Division, Hospital Doctor Negrin, Las Palmas GC, Spain, ⁵Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain, ⁶Rheumatology Department, Hospital Universitario Araba. Vitoria-Gasteiz, Alava, Spain, ⁷Rheumatology, Hospital general Universitario Gregorio Marañón, Madrid, Spain, ⁸Rheumatology, Hospital General Universitario Gregorio Marañón, Genoa, Italy, ⁹Servicio de Reumatología, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ¹⁰Complexo Hospitalario Universitario de Vigo, Vigo, Spain
Background/Purpose: The clinical coexistence of Systemic Lupus Erythematosus (SLE) and Sjögren's Syndrome (SS) was recognized in 1959. The prevalence of SS among patients with SLE…
Abstract Number: 1381 • 2018 ACR/ARHP Annual Meeting
Association of Omeract Core Domains of Pain and Function with Patient Satisfaction after Total Joint Replacement
Susan M. Goodman¹, Bella Y. Mehta², Lisa A. Mandl³, Jackie Szymonifka¹, Mark P. Figgie⁴, Iris Navarro-Millán⁵, Mathias Bostrom⁶, Michael L. Parks⁷, Alexander McLawhorn⁸, Stephen Lyman⁷ and Jasvinder A. Singh⁹, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery/Weill Cornell Medicine/Mailman School of Public Health, New York, NY, ³Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Surgery, Hospital for Special Surgery, New York, NY, ⁵Weill Cornell Medicine, New York, NY, ⁶Orthopaedic Surgery, Hospital for Special Surgery, New York, NY, ⁷Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁸Hospital for Special Surgey, New York, NY, ⁹Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Up to 20% of Total Joint Replacement (TJR) patients are dissatisfied, but this is difficult to study as it is challenging to pool data…
Abstract Number: 2673 • 2018 ACR/ARHP Annual Meeting
Different Risk Profiles for Development of Steroid-Related and Steroid-Unrelated Damage in Early Diagnosed SLE: Results from the Italian Multicenter Early Lupus Project Inception Cohort
Matteo Piga¹, Gian Domenico Sebastiani², Imma Prevete³, Florenzo Iannone⁴, Laura Coladonato⁵, Marcello Govoni⁶, Alessandra Bortoluzzi⁷, Marta Mosca⁸, Chiara Tani⁸, Andrea Doria⁹, Luca Iaccarino¹⁰, Angela Tincani¹¹, Micaela Fredi¹², Fabrizio Conti¹³, Francesca Spinelli¹⁴, Mauro Galeazzi¹⁵, Francesca Bellisai¹⁶, Anna Zanetti¹⁷, Greta Carrara¹⁸, Carlo Alberto Scirè¹⁹ and Alessandro Mathieu¹, ¹Unit and Chair of Rheumatology, University Hospital of Cagliari, Cagliari, Italy, ²Rheumatology, San Camillo Forlanini Hospital, Roma, Italy, ³Azienda Ospedaliera San Camillo of Rome, Roma, Italy, ⁴Reumatologia Universita e Policlinico di Bari, Bari, Italy, ⁵Reumatologia, Università e Policlinico di Bari, Bari, Italy, ⁶UOC of Rheumatology, University Hospital S. Anna, Cona Ferrara, Italy, ⁷Section of Rheumatology, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliera-University Hospital S. Anna, Cona Ferrara, Italy, ⁸Rheumatology Unit, University of Pisa, Pisa, Italy, ⁹University and Azienda Ospedaliera of Padova, Padova, Italy, ¹⁰Department of Medicine-DIMED, University of Padova, Padova, Italy, ¹¹Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Brescia, Italy, Rheumatology and Clinical Immunology, BRESCIA, Italy, ¹²Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Brescia, Italy, Rheumatology and Clinical Immunology, Brescia, Italy, ¹³Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy, ¹⁴Dipartimento di Medicina Interna e Specialita` Mediche, Sapienza Universita` di Roma, Roma, Italy, ¹⁵Rheumatology, University Hospital of Siena, Siena, Italy, ¹⁶UOC di Reumatologia, Azienda Ospedaliera Universitaria Senese, Siena, Italy, ¹⁷Italian Society for Rheumatology, Milano, Italy, ¹⁸Epidemiology Unit, Italian Society for Rheumatology, Milano, Italy, ¹⁹Italian Society for Rheumatology, Milan, Italy
Background/Purpose:Preventing organ damage is a major challenge in Systemic Lupus Erythematosus (SLE).To evaluate factors associated with development of steroid-related and unrelated damage in an inception…
Abstract Number: 1438 • 2018 ACR/ARHP Annual Meeting
Treatment and Response of Down Syndrome Arthropathy
Jordan T. Jones¹, Nasreen Talib², Daniel J Lovell³ and Mara L Becker⁴, ¹Rheumatology Division, Children's Mercy Kansas City, Kansas City, MO, ²General Pediatrics, Children's Mercy Kansas City, Kansas City, MO, ³Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Rheumatology, Children's Mercy Kansas City, Kansas City, MO
Background/Purpose: Of the very few studies describing Down syndrome arthropathy (DA), crude prevalence estimates indicate DA maybe as common as juvenile idiopathic arthritis (JIA), however,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].